Rifamycins as inhibitors of retroviral reverse transcriptase from M-MuLV, RAV-2, and HIV-1

C. Bartolucci, L. Cellai, P. Di Filippo, A. Segre, M. Brufani, L. Filocamo, A. D. Bianco, M. Guiso, V. Brizzi, A. Benedetto, A. Di Caro, G. Elia

Research output: Contribution to journalArticlepeer-review

Abstract

29 Rifamycins were tested for inhibition of Reverse Transcriptase (RT) as potential anti HIV drugs. Two purified commercial enzymes from M-MuLV and RAV-2 were used. Anti-RT activity was also measured on a crude lysate of HIV-1. The results show that some derivatives have interesting levels of activity on isolated M-MuLV and RAV-2 RTs, while they are less active on the RT in the crude HIV-1 lysate. The active derivatives include oximes and hydrazones, alkylaminoderivatives, open ansa-chain derivatives and derivatives carrying a modified nucleoside.

Original languageEnglish
Pages (from-to)1367-1383
Number of pages17
JournalFarmaco
Volume47
Issue number11
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Rifamycins as inhibitors of retroviral reverse transcriptase from M-MuLV, RAV-2, and HIV-1'. Together they form a unique fingerprint.

Cite this